Daily Briefing

5 minute read

Health policy roundup: Heidi Overton dropped as pick for FDA commissioner


The White House on Tuesday said it's pulling the nomination of Heidi Overton to be commissioner of FDA amid concerns that she likely didn't have the votes to be confirmed by the Senate, in today's roundup of the news in healthcare politics.

White House withdraws FDA commissioner nomination

The White House on Tuesday said it's pulling the nomination of Heidi Overton to be commissioner of FDA amid growing signs that she likely didn't have the votes to win Senate confirmation.

In May, Marty Makary resigned as FDA commissioner following reports that the White House had planned to fire him. Then, in August, President Donald Trump nominated Overton, deputy director of domestic policy for the White House, to serve as the next FDA commissioner.

The announcement of the withdrawal came the night before Overton's nomination was up for a vote from the Senate health committee, where she had faced bipartisan questions about her willingness to break from Trump, especially on his administration's approach to vaccines.

Sen. Bill Cassidy (R-La.), a doctor who chairs the committee, previously indicated that he was undecided about Overton. If Overton's nomination were to advance beyond the health committee, she would have needed every Republican on the committee to vote for her.

However, following the announcement that Overton's nomination had been withdrawn, Cassidy said in a social media post that the White House "abandoned" Overton and suggested she may have had the votes to pass through the health committee.

"I believe she would have had the votes to pass out of committee and pass the full Senate," Cassidy said. "My conversations with her convinced me she would follow the science and push back against decisions that put Americans' health at risk."

It's unclear whether the White House will choose another nominee to lead FDA before January when Democrats will take control of the Senate. Cassidy said he believes that "with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats."

(Perrone/Kim, Associated Press, 11/18; Manto/Payne, STAT+ [subscription required], 11/17; Jewett, New York Times, 11/17)

CMS unveils new rule aimed at addressing fraud, waste, and abuse

CMS on Monday unveiled the draft Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) proposed rule, which aims to improve oversight of Medicaid and Medicare as well as the agency's ability to find and prevent fraud, waste, and abuse across federal healthcare programs.

Specifically, CRUSH addresses Medicare Advantage's (MA) payments that are not backed by a diagnosis, expands reporting requirements for Medicaid, and strengthens CMS' authority to terminate any agents or brokers on the health insurance marketplace.

The proposed rule would strengthen MA Risk Adjustment Data Validation audits in order to "identify and recover improper payments when beneficiary diagnosis data, submitted to CMS by MA organizations for the purpose of receiving risk adjusted payments, is not supported by medical record documentation and found to have improperly inflated beneficiary risk scores," CMS said in a release.

"Specifically, CMS is proposing to codify that it would not apply a fee-for-service (FFS) adjuster, would determine the applicable sampling methodology, and would begin extrapolation of audit findings with payment year (PY) 2018 audits," the agency said in a fact sheet.

In February, CMS issued a formal request for information on CRUSH as part of a larger crackdown on fraud that included withholding Medicaid funds from Minnesota and freezing Medicare enrollments for new durable medical equipment suppliers.

"When President Trump called upon the federal government to crush fraud, waste and abuse, CMS got right to work," said CMS Administrator Mehmet Oz in a statement. "CRUSH would build on those results by giving us stronger tools to prevent fraud, remove bad actors and protect the Americans who rely on these programs."

(Lotven, Inside Health Policy [subscription required], 11/16; Early, Modern Healthcare, 11/16)

Supreme Court rejects Trump administration appeal on DEI funding cuts

The Supreme Court on Monday rejected the Trump administration's appeal on diversity, equity, and inclusion (DEI) funding cuts to academic research, leaving in place lower court rulings that found the administration likely violated the First Amendment when it terminated millions of dollars in grants to researchers at the University of California.

The cuts occurred after the Trump administration issued an executive order in January 2025 that required the federal government to end programs linked to DEI, arguing the government is not obligated to continue funding any research that doesn't fit its priorities.

The lawsuit, which only involved a portion of the funding cuts, was originally brought to the Northern District of California by researchers who challenged the termination of the grants. The plaintiffs argued the grant terminations were "unconstitutional and otherwise unlawful because they violate the bedrock constitutional principle of separation of powers; the First Amendment guarantee of free speech; the Fifth Amendment guarantee of due process; the Impoundment Control Act of 1974; statutes requiring agencies to fulfill congressionally defined missions; and the Administrative Procedure Act."

District Court Judge Rita Lin ordered the federal government to restore the grants, a ruling that was later upheld by the Ninth Circuit Court of Appeals in May, with that panel of justices saying that since the grant terminations were "aimed at the suppression of viewpoints with which the government disagrees, it likely violates the First Amendment."

(Whitehurst, Associated Press, 11/16; Karins, Inside Health Policy [subscription required], 11/16)

Congressional Democrats working on 'Medicare for More' and 'MediKids' proposals

House Minority Leader Hakeem Jeffries (D-N.Y.), who is expected to be the next House Majority Leader, endorsed two healthcare proposals around providing Medicare to more Americans at the What's Next conference on Friday — an event where party leaders and newly elected lawmakers discussed their agenda for next year. 

One proposal, called "MediKids," would provide free health insurance to everyone from birth until age 26, while another, referred to as "Medicare for More," would expand access to the Medicare program to more Americans and add coverage for dental and vision care.

As part of his push to expand Medicare, Sen. Bernie Sanders (I-Vt.) recently outlined a plan that would lower the Medicare eligibility age by 10 years, include vision and dental care in Medicare, and guarantee health insurance for all children up through age 19.

Sanders argued this plan would push the United States toward "Medicare for All."

"The American people want change — real change," Sanders said, adding that lawmakers "cannot continue the same old, same old establishment politics and establishment policies."

"I think we've got to lower the age of eligibility as it relates to Medicare," Jeffries said. "I think we gotta make sure we cover hearing, vision, and dental. And we've got to make sure that every child in America can be able to see a doctor with high-quality, affordable healthcare."

Jeffries added that the party has to first undo cuts to Medicaid funding under the One Big Beautiful Bill Act and restore the enhanced premium tax credits for the Affordable Care Act insurance that expired at the end of 2025.

(Wilkerson, STAT+ [subscription required], 11/13; Payne, STAT+ [subscription required], 11/9)


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

RELATED RESOURCES

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece

Email ask@advisory.com to learn more

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

This is for members only. Learn more.

Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board

Never miss out on the latest innovative health care content tailored to you. 

Benefits Include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.